MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/03/6406-1521-1529$20.00
Mol Pharmacol 64:1521-1529, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikezoe, T.
Right arrow Articles by Koeffler, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikezoe, T.
Right arrow Articles by Koeffler, H. P.

PC-SPES: A Potent Inhibitor of Nuclear Factor-{kappa}B Rescues Mice from Lipopolysaccharide-Induced Septic Shock

Takayuki Ikezoe, Yang Yang, David Heber, Hirokuni Taguchi, and H. Phillip Koeffler

Division of Hematology/Oncology (T.I., H.P.K.), Cedars-Sinai Medical Center (D.H.), Clinical Nutrition, UCLA School of Medicine, Los Angeles, California; and Department of Internal Medicine (T.I., Y.Y., H.T.), Kochi Medical School, Kochi, Japan

Septic shock is the most common cause of death in intensive care units, and no effective treatment is available at present. Lipopolysaccharide (LPS) is the primary mediator of Gram-negative sepsis by inducing the production of macrophage-derived proinflammatory cytokines, in which activation of nuclear factor-{kappa}B (NF-{kappa}B) plays an important role. PC-SPES is an eight-herb mixture active against a variety of malignancies, including prostate cancer and leukemia. In this study, we demonstrated that PC-SPES inhibited the LPS-induced NF-{kappa}B reporter activity in RAW264.7 macrophages. Electrophoretic mobility shift assay showed that PC-SPES inhibited the binding of NF-{kappa}B to specific DNA sequences; however, it did not affect either degradation of inhibitory {kappa}B{alpha} or nuclear translocation of NF-{kappa}B. Also, we explored the effect of PCSPES on LPS-induced mitogen-activated protein (MAP) kinase signaling; PC-SPES did not affect LPS-induced phosphorylation of MAP kinases, including c-Jun NH2-terminal kinase, p38, and extracellular signal-regulated kinase 1/2. Moreover, PC-SPES decreased the production of proinflammatory cytokines and inducible enzymes, such as tumor necrosis factor (TNF) {alpha}, interleukin (IL)-1{beta}, IL-6, cyclooxygenase-2, as well as inducible nitric-oxide synthase in RAW264.7 macrophages and peritoneal macrophages from C57BL/6 mice after the cells were stimulated by either LPS or LPS and interferon-{gamma}. Furthermore, PC-SPES rescued C57BL/6 mice from death caused by LPS-induced septic shock in conjunction with decreased serum levels of TNF{alpha} and IL-1{beta}. Together, PC-SPES is a potent inhibitor of NF-{kappa}B and might be useful for the treatment of sepsis and inflammatory diseases.


Received March 28, 2003; accepted September 10, 2003

Address correspondence to: Dr. Takayuki Ikezoe, Department of Internal Medicine, Kochi Medical School, Nankoku, Kochi 783-8505, Japan. E-mail: ikezoet{at}med.kochi-ms.ac.jp




This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. F. Liu and A. B. Malik
NF-{kappa}B activation as a pathological mechanism of septic shock and inflammation
Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L622 - L645.
[Abstract] [Full Text] [PDF]


Home page
JPEN J Parenter Enteral NutrHome page
S. Bengmark
Curcumin, An Atoxic Antioxidant and Natural NF{kappa}B, Cyclooxygenase-2, Lipooxygenase, and Inducible Nitric Oxide Synthase Inhibitor: A Shield Against Acute and Chronic Diseases
JPEN J Parenter Enteral Nutr, January 1, 2006; 30(1): 45 - 51.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. J. Kwak, J. S. Song, J. Y. Heo, S. D. Yang, J.-Y. Nam, and H. G. Cheon
Roflumilast Inhibits Lipopolysaccharide-Induced Inflammatory Mediators via Suppression of Nuclear Factor-{kappa}B, p38 Mitogen-Activated Protein Kinase, and c-Jun NH2-Terminal Kinase Activation
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1188 - 1195.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Ikezoe, Y. Yang, K. Bandobashi, T. Saito, S. Takemoto, H. Machida, K. Togitani, H. P. Koeffler, and H. Taguchi
Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-{kappa}B signal pathways
Mol. Cancer Ther., April 1, 2005; 4(4): 578 - 586.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. L. McCoy, S. E. Kurtz, C. J. MacArthur, D. R. Trune, and S. H. Hefeneider
Identification of a Peptide Derived from Vaccinia Virus A52R Protein That Inhibits Cytokine Secretion in Response to TLR-Dependent Signaling and Reduces In Vivo Bacterial-Induced Inflammation
J. Immunol., March 1, 2005; 174(5): 3006 - 3014.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics